

# Y-27632 dihydrochloride

Catalog Number: C629401



**OrganRegen, INC.**  
Creating Solutions for Organoid Cultures

## DESCRIPTION

**Background** Y-27632 dihydrochloride is an orally active, ATP-competitive inhibitor of ROCK-I and ROCK-II, with  $K_{i}$ s of 220 and 300 nM, respectively. Y-27632 dihydrochloride attenuates Doxorubicin-induced apoptosis of human cardiac stem cells. Y-27632 also suppresses dissociation-induced apoptosis of murine prostate stem/progenitor cells. Y-27632 dihydrochloride primes human induced pluripotent stem cells (hIPSCs) to selectively differentiate towards mesendodermal lineage via epithelial-mesenchymal transition-like modulation<sup>[1][2][3][4][5]</sup>.


**M. W t** 320.26

**Formula**  $C_{14}H_{23}Cl_2N_3O$

**CAS No** 129830-38-2

**Storage** Powder -20 °C 3 years  
In solvent -80°C 6 months  
-20 °C 1 month

**Solubility** DMSO 33.33 mg/mL(104.07 mM; Need ultrasonic)  
H<sub>2</sub>O 100 mg/mL(312.25 mM; Need ultrasonic)



## BIOLOGICAL ACTIVITY

### In Vitro

Y-27632 inhibits the ROCK family of kinases 100 times more potently than other kinases including protein kinase C, cAMP-dependent kinase and myosin light chain kinase. Y-27632 prolongs the lag time and delays the appearance of BrdU-labeled cells in a concentration-dependent manner, delays of about 1 and 4 h are noticed in the Swiss 3T3 cells treated with 10 and 100  $\mu$ M Y-27632, respectively<sup>[1]</sup>.

Y-27632 promotes neuronal differentiation of adipose tissue-derived stem cells (ADSCs). Compared to 1.0 and 2.5  $\mu$ M Y-27632 induced groups, percentages of neuroal-like cells achieved a peak in the 5.0  $\mu$ M Y-27632 induced group<sup>[2]</sup>.

### In Vivo

Y-27632 (5 and 10 mg/kg) significantly prolongs the onset time of myoclonic jerks when compare with saline group. Y-27632 (5 and 10 mg/kg) significantly prolongs the onset time of clonic convulsions when compare with saline group<sup>[3]</sup>.

Treatment with Dimethylnitrosamine (DMN) causes a significant decrease in rat body and liver weight (DMN-S group) compared with control animals (S-S group). Oral Y27632 (30 mg/kg) essentially prevents this DMN-induced rat body and liver weight loss (DMN-Y group)<sup>[4]</sup>.

## REFERENCES

[1]. Ishizaki T, et al. Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. *Mol Pharmacol*. 2000 May;57(5):976-83.

[2]. Xue ZW, et al. Rho-associated coiled kinase inhibitor Y-27632 promotes neuronal-like differentiation of adult human adipose tissue-derived stem cells. *Chin Med J (Engl)*. 2012 Sep;125(18):3332-5.

[3]. Tada S, et al. A selective ROCK inhibitor, Y27632, prevents dimethylnitrosamine-induced hepatic fibrosis in rats. *J Hepatol*. 2001 Apr;34(4):529-36.

[4]. Inan S, et al. Antiepileptic effects of two Rho-kinase inhibitors, Y-27632 and fasudil, in mice. *Br J Pharmacol*. 2008 Sep;155(1):44-51.

[5]. Maldonado M, et al. ROCK inhibitor primes human induced pluripotent stem cells to selectively differentiate towards mesendodermal lineage via epithelial-mesenchymal transition-like modulation. *Stem Cell Res*. 2016 Sep;17(2):222-227.